2020
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
Romani C, Zizioli V, Silvestri M, Ardighieri L, Bugatti M, Corsini M, Todeschini P, Marchini S, D'Incalci M, Zanotti L, Ravaggi A, Facchetti F, Gambino A, Odicino F, Sartori E, Santin AD, Mitola S, Bignotti E, Calza S. Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. Frontiers In Oncology 2020, 10: 1287. PMID: 32850397, PMCID: PMC7417514, DOI: 10.3389/fonc.2020.01287.Peer-Reviewed Original ResearchHigh-grade serous ovarian carcinomaDistant metastasisClaudin-7High-grade serous ovarian carcinoma patientsSerous ovarian carcinoma patientsClaudin-3Distant hematogenous metastasisDistant metastatic eventsNormal tubal epitheliumSite of metastasisOvarian carcinoma patientsSerous ovarian carcinomaFallopian tube epitheliumExpression levelsNormal fallopian tube epitheliumTight junction proteinsExpression of claudinsHematogenous recurrenceRoutes of disseminationQuantitative RT-PCRDistant diseaseHematogenous routeCarcinoma patientsClinicopathological featuresHGSOC patients
2011
erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
ElSahwi KS, Santin AD. erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics And Gynecology International 2011, 2011: 128295. PMID: 21876697, PMCID: PMC3159302, DOI: 10.1155/2011/128295.Peer-Reviewed Original ResearchUterine serous adenocarcinomaERBB2 overexpressionEndometrial cancerCommon female genital tract malignancyFemale genital tract malignanciesType I endometrial cancerGenital tract malignanciesUterine serous cancerViable treatment optionSerous cancerStandard chemotherapyWorse survivalLymph nodesTrastuzumab therapyBetter prognosisDistant metastasisSerous adenocarcinomaTreatment optionsCase reportRecurrent casesBreast cancerHumanized mAbTrastuzumab activityType II variantCancer relapse